Search

There is an increasing interest in nootropic drugs for the treatment of CNS disorders. Since the last meta-analysis of the clinical efficacy of piracetam, more information has accumulated. The primary objective of this systematic survey is to evaluate the clinical outcomes as well as the scientific literature relating to the pharmacology, pharmacokinetics/pharmacodynamics, mechanism of action, dosing, toxicology and adverse effects of marketed and investigational drugs. The major focus of the literature search was on articles demonstrating evidence-based clinical investigations during the past 10 years for the following therapeutic categories of CNS disorders: (i) cognition/memory; (ii) epilepsy and seizure; (iii) neurodegenerative diseases; (iv) stroke/ischaemia; and (v) stress and anxiety. In this article, piracetam-like compounds are divided into three subgroups based on their chemical structures, known efficacy and intended clinical uses. Subgroup 1 drugs include piracetam, oxiracetam, aniracetam, pramiracetam and phenylpiracetam, which have been used in humans and some of which are available as dietary supplements. Of these, oxiracetam and aniracetam are no longer in clinical use. Pramiracetam reportedly improved cognitive deficits associated with traumatic brain injuries. Although piracetam exhibited no long-term benefits for the treatment of mild cognitive impairments, recent studies demonstrated its neuroprotective effect when used during coronary bypass surgery. It was also effective in the treatment of cognitive disorders of cerebrovascular and traumatic origins; however, its overall effect on lowering depression and anxiety was higher than improving memory. As add-on therapy, it appears to benefit individuals with myoclonus epilepsy and tardive dyskinesia. Phenylpiracetam is more potent than piracetam and is used for a wider range of indications. In combination with a vasodilator drug, piracetam appeared to have an additive beneficial effect on various cognitive disabilities. Subgroup 2 drugs include levetiracetam, seletracetam and brivaracetam, which demonstrate antiepileptic activity, although their cognitive effects are unclear. Subgroup 3 includes piracetam derivatives with unknown clinical efficacies, and of these nefiracetam failed to improve cognition in post-stroke patients and rolipram is currently in clinical trials as an antidepressant. The remaining compounds of this subgroup are at various preclinical stages of research. The modes of action of piracetam and most of its derivatives remain an enigma. Differential effects on subtypes of glutamate receptors, but not the GABAergic actions, have been implicated. Piracetam seems to activate calcium influx into neuronal cells; however, this function is questionable in the light of findings that a persistent calcium inflow may have deleterious impact on neuronal cells. Although subgroup 2 compounds act via binding to another neuronal receptor (synaptic vesicle 2A), some of the subgroup 3 compounds, such as nefiracetam, are similar to those of subgroup 1. Based on calculations of the efficacy rates, our assessments indicate notable improvements in clinical outcomes with some of these agents. [ABSTRACT FROM AUTHOR]

A number of novel biotin phosphoramidites, possessing exceptionally long and uncharged tethering arms, were synthesized from methoxyoxalamido (MOX) and succinimido (SUC) precursors. Included among these monomers is a uridine derivative with the biotin moiety attached through the 2'-position. Some of these phosphoramidites were used to make 5'-biotinylated primers, which were applied in direct sequencing of genomic DNA and capture of Sanger fragment pools.

A novel repeated sequence of chaffinch (Fringilla coelebs) designated as GS was isolated from genomic DNA after in vitro amplification of satellite DNA sequences using GSP-PCR technique. The proportion of this repeat in the chaffinch genome constitutes about 2%. Monomers are 176 to 199 bp in size and contain a short cluster of the TTAGGG telomeric tandem repeat. The oligomer of the telomeric hexanucleotide is flanked by the sequences that are significantly different in different monomers. The GS sequences are organized as tandemly repeated units and located in a number of chromomycin-positive blocks on the long arms of macrochromosomes 1, 2, 3, 5, and 6, as well as on several microchromosomes. The sequences homologous to the GS satellite of chaffinch were not found in the genomes of redwing (Turdus iliacus) and house sparrow (Passer domesticus).

We have determined the complete 1,694,969-nt sequence of the GC-rich genome of Methanopyrus kandleri by using a whole direct genome sequencing approach. This approach is based on unlinking of genomic DNA with the ThermoFidelase version of M. kandleri topoisomerase V and cycle sequencing directed by 2'-modified oligonucleotides (Fimers). Sequencing redundancy (3.3x) was sufficient to assemble the genome with less than one error per 40 kb. Using a combination of sequence database searches and coding potential prediction, 1,692 protein-coding genes and 39 genes for structural RNAs were identified. M. kandleri proteins show an unusually high content of negatively charged amino acids, which might be an adaptation to the high intracellular salinity. Previous phylogenetic analysis of 16S RNA suggested that M. kandleri belonged to a very deep branch, close to the root of the archaeal tree. However, genome comparisons indicate that, in both trees constructed using concatenated alignments of ribosomal proteins and trees based on gene content, M. kandleri consistently groups with other archaeal methanogens. M. kandleri shares the set of genes implicated in methanogenesis and, in part, its operon organization with Methanococcus jannaschii and Methanothermobacter thermoautotrophicum. These findings indicate that archaeal methanogens are monophyletic. A distinctive feature of M. kandleri is the paucity of proteins involved in signaling and regulation of gene expression. Also, M. kandleri appears to have fewer genes acquired via lateral transfer than other archaea. These features might reflect the extreme habitat of this organism.

A highly repetitive centromeric Fringilla coelebs PstI (FCP) element was cloned and sequenced. The FCP tandem repeats with unit 505 or 506 nt accounted for about 0.9% of the entire genome and had 57% GC. Direct genomic sequencing with FCP-specific primers and ThermoFidelase 2A revealed the consensus sequence and the five most common single-nucleotide polymorphisms (SNPs) for the FCP unit. FCP may be transcribed and may play a role in spatial arrangement of the genome.

Combinations of drugs targeting viral proteins have been used to limit or control drug resistance, which is the most important cause of treatment failure in HIV-1-infected individuals. We suggest an alternative approach, namely to target cellular proteins, which are less prone to mutations than viral proteins. Here we show that simultaneous inhibition of a cellular protein (by hydroxyurea) and a viral protein (by ddI) produces a consistent and sustained suppression of HIV-1 for as long as 40 weeks in the absence of virus rebound. We identified the mechanism to explain this lack of rebound: although the combination of the two drugs did not prevent the emergence of mutant viral strains resistant to didanosine (ddI) in these patients, the mutants were still sensitive to standard doses of ddI in the presence of hydroxyurea. These in vivo results were consistent with our in vitro observations: HIV-1 molecular clones resistant to ddI were rendered sensitive to this drug (at concentrations routinely achievable in vivo) after addition of hydroxyurea. This phenomenon can be explained by the observation that hydroxyurea decreases the level of dATP, the cellular competitor of ddI. A low level of dATP favors the incorporation of ddI, even if the viral reverse transcriptase is resistant to this nucleoside analog. This is a novel mechanism of control of resistance and it explains the efficacy of a treatment that is well tolerated, simple, and inexpensive.

Overall HIV-1 prevalence in St. Petersburg (Leningrad) is extremely low (0.002%). HIV-2 infection has not been detected. The possible mode of virus entry was through sexual contacts with infected foreigners, the earliest documented date being prior to 1982. Among 25 seropositive males, 18 are homosexual and five are bisexual, suggesting that the virus is circulating within resident population of homo/bisexual males. The total incidence of new infections has not shown the type of dramatic increase noted in US gay/bisexual men in early 1980s. Information on lifestyle characterization of this indigenous population require further study to determine the future potential for spread. Among the non-Soviet population the rate is 0.01%. Highest rates occur among persons from HIV endemic areas of Africa, with rates as high as 5% and 3% among persons from Uganda and Rwanda, respectively. Rates among new entrants from Africa are lower, possibly reflecting the impact of prescreening of applicants prior to arrival in Russia. Further monitoring of high-risk populations and studies to define behavior risk pattern are planned.

Cells from anti-HIV-positive persons were used in experiments for virus isolation. The RT-activity, viral antigen, nucleic acids, electron microscopic morphology, and infectivity were studied. The data presented allow a conclusion that the virus was isolated. These data confirmed the previous diagnosis of HIV infection.